STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 September 2003 please refer to module 8B. 
Scope 
Application 
number 
Type of 
modification1 
Change to the manufacturing process of the active substance 
Additional presentations: Lantus OptiSet, solution for injection in 
3 ml pre-filled pens: packs of 3, 4, 5 and 10 pens 
Change to the manufacturing process of the active substance 
Demonstration of TSE compliance 
Change in the insulin glargine production process 
Addition of a new volume vial of 10 ml 
The indication has been extended for the use of Lantus in children 
of  6  years  or  above.  In  addition  a  class  wording  regarding 
hypoglycaemic reactions after transfer from animal source insulin 
to human insulin has been included in section 4.4 of the SPC.  
The Package Leaflet has been updated accordingly. 
Change in the dosing scheme for Lantus with the consequent 
change in section 4.2 of the SPC. In addition a warning 
concerning “hypoglycaemia” has been included in section 4.4 of 
the SPC. The Package Leaflet has been updated accordingly.  
Notification/ 
Opinion 
issued on2 
19/10/2000 
Commission 
Decision 
Issued/amended 
on 
- 
19/10/2000 
06/02/2001 
01/03/2001 
26/04/2001 
27/06/2001 
- 
- 
- 
26/07/2001 
28/01/2002 
21/11/2002 
04/03/2003 
II/0001 
II/0002 
II/0003 
II/0004 
II/0005 
II/0006 
II/0007 
II 
II 
II 
II 
II 
II 
II 
II/0008 
II 
19/09/2002 
05/12/2002 
Additional  presentations:  packs  of  1,  3,  6,  8,  9  cartridges  and 
packs of 1, 6, 8, 9 pre-filled pens (OptiSet). 
I/0009 
I 
19/03/2003 
22/04/2003 
Change in the batch size of finished product 
Change  in  supplier  of  an  intermediate  compound  used  in 
manufacture of the active substance 
Minor change in the labelling 
I/0010 
I/0011 
N/0013 
I/II 
25/04/2003 
I 
N 
19/06/2003 
29/08/2003 
- 
- 
- 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 61(3) of Directive 2001/83/EC of 6 November 2001. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
 
 
